Quantcast

Latest 3-Aminopyridine-2-carboxaldehyde thiosemicarbazone Stories

2009-12-17 14:35:00

NEW HAVEN, Conn., Dec. 17 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION), a pharmaceutical company focused on the development of novel cancer therapeutics, announced that it had voluntarily filed for bankruptcy under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware. Vion is continuing to operate its business as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy...

2009-11-10 15:30:00

NEW HAVEN, Conn., Nov. 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced financial results for the three-month and nine-month periods ending September 30, 2009. For the third quarter of 2009, the Company reported a net loss of $6.2 million, or $0.78 per share, compared with a net loss of $6.8 million, or $0.92 per share, for the same 2008 period. Weighted-average common shares outstanding for the three-month periods ended September 30, 2009...

2009-10-12 15:00:00

NEW HAVEN, Conn., Oct. 12 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) announced today that it had hired the investment banking firm Merriman Curhan Ford & Co. to assist in evaluating its strategic alternatives. These alternatives include any combination of a restructuring of the Company and its debt and a sale of the Company or its assets. The Company may also consider financing options. As previously reported, the Oncologic Drugs Advisory...

2009-09-09 07:00:00

NEW HAVEN, Conn., Sept. 9 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that it would make a corporate presentation at the 11th Annual Rodman & Renshaw Healthcare Conference in New York City. The presentation will be on Thursday, September 10, 2009 at 5:45 p.m. in the Hubbard Salon, 5th Floor, of the New York Palace Hotel. Slides from the presentation will be available on the Company's website, www.vionpharm.com, at the time of the...

2009-09-02 07:00:00

NEW HAVEN, Conn., Sept. 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced the results of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which data for its lead oncology therapeutic Onrigin(TM)(laromustine) Injection were presented for the indication of remission induction treatment for patients sixty years of age or older with de novo poor-risk acute myeloid leukemia (AML). The ODAC was asked by the U.S. Food and Drug...

2009-08-11 07:00:00

NEW HAVEN, Conn., Aug. 11 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced financial results for the three-month and six-month periods ending June 30, 2009. For the second quarter of 2009, the Company reported a net loss of $6.6 million, or $0.83 per share compared with a net loss of $7.9 million, or $1.06 per share, for the same 2008 period. Weighted-average common shares outstanding for the three months ended June 30, 2009 and June 30, 2008...

2009-08-10 11:27:00

NEW HAVEN, Conn., Aug. 10 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced the date and location of the Oncologic Drugs Advisory Committee (ODAC) Meeting at which its lead oncology therapeutic Onrigin(TM) (laromustine) Injection will be presented. The ODAC reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in the treatment of cancer and makes appropriate...

2009-06-01 07:00:00

NEW HAVEN, Conn., June 1 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC BULLETIN BOARD: VION) today announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in patients over the age of sixty with acute myeloid leukemia (AML) was presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. Ann Cahill, Vice President, Clinical Development, commented, "This poster presents an...

2009-05-29 07:00:00

NEW HAVEN, Conn., May 29 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced that an analysis of clinical data of its lead anticancer agent Onrigin (laromustine) Injection in acute myeloid leukemia (AML) would be presented in a poster at the 2009 American Society of Clinical Oncology (ASCO) Annual Meeting in Orlando, Florida. The poster (Abstract #7050) entitled "Comorbidity Description Using the Hematopoietic Cell Transplantation-Specific...

2009-05-11 15:30:00

Company to hold Conference Call on May 14, 2009 NEW HAVEN, Conn., May 11 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (OTC Bulletin Board: VION) today announced financial results for the first quarter of 2009. The Company reported a net loss of $4.3 million, or $0.54 per share, for the quarter ended March 31, 2009, compared with a net loss of $8.2 million, or $1.14 per share, for the same 2008 period. Weighted-average common shares outstanding for the three months ended March...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.